INSM Share Price

Open 15.63 Change Price %
High 16.81 1 Day 0.88 5.57
Low 15.60 1 Week 1.33 8.66
Close 16.69 1 Month 0.76 4.77
Volume 230393 1 Year 5.16 44.75
52 Week High 17.32
52 Week Low 9.02
INSM Important Levels
Resistance 2 17.81
Resistance 1 17.35
Pivot 16.37
Support 1 16.03
Support 2 15.57
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
MU 28.76 1.16%
MU 28.76 1.16%
MU 28.76 1.16%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
IPXL 12.70 37.30%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
RGLS 1.70 21.43%
SCON 1.54 19.38%
CPRX 2.01 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Insmed, Inc. (NASDAQ: INSM)

INSM Technical Analysis 5
As on 27th Mar 2017 INSM Share Price closed @ 16.69 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 13.25 & Strong Buy for SHORT-TERM with Stoploss of 15.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
INSM Target for March
1st Target up-side 17.53
2nd Target up-side 18.66
3rd Target up-side 19.78
1st Target down-side 14.33
2nd Target down-side 13.2
3rd Target down-side 12.08
INSM Other Details
Segment EQ
Market Capital 202974992.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.insmed.com
INSM Address
INSM
9 Deer Park Drive
Suite C
Monmouth Junction, NJ 08852
United States
Phone: 732-997-4600
INSM Latest News
Interactive Technical Analysis Chart Insmed, Inc. ( INSM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Insmed, Inc.
INSM Business Profile
Insmed Incorporated is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies. The Company�s lead candidate ARIKACE, is engineered to deliver anti-infective directly to the site of lung infections for at least two identified patient populations: cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). During the year ended December 31, 2011, the Company was focused on its ARIKACE clinical development program, which includes a phase II clinical study of ARIKACE in patients with NTM lung disease (TARGET-NTM), as well as a European and Canadian registration phase III clinical study of ARIKACE in CF patients with Pseudomonas lung infections (CLEAR-108). ARIKACE is considered a New Chemical Entity by the United States Food and Drug Administration (FDA), primarily due to its liposomal technology.